Patents Assigned to Millenium Pharmaceuticals, Inc.
-
Patent number: 6642039Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.Type: GrantFiled: February 22, 2001Date of Patent: November 4, 2003Assignee: Millenium Pharmaceuticals, Inc.Inventors: William James Cook, Rory A. J. Curtis, Frank Spaltmann
-
Patent number: 6627747Abstract: Disclosed are two genes, termed “yphC” and “yqjK,” found in Streptococcus pneumoniae, which are essential for survival for a wide range of bacteria. These genes and the essential polypeptides that they encode, as well as homologs and orthologs thereof, can be used to identify antibacterial agents for treating a broad spectrum of bacterial infections.Type: GrantFiled: September 9, 1999Date of Patent: September 30, 2003Assignee: Millenium Pharmaceuticals, Inc.Inventors: Christian Fritz, Philip Youngman, Luz-Maria Guzman
-
Patent number: 6514715Abstract: Disclosed are essential Aspergillus polypeptides and genes (AN97, AN17, AN80, and AN85), as well as homologs thereof, which can be used to identify antifungal agents for treating fungal infections such as aspergillosis.Type: GrantFiled: July 23, 2001Date of Patent: February 4, 2003Assignee: Millenium Pharmaceuticals, Inc.Inventors: Yigal Koltin, Victoria Gavrias
-
Publication number: 20030022170Abstract: The present invention relates to the discovery of novel genes encoding a fibroblast growth factor, MFGF. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: ApplicationFiled: March 29, 2001Publication date: January 30, 2003Applicant: Millenium Pharmaceuticals, Inc.Inventor: Mehran Mohamad Khodadoust
-
Patent number: 6448021Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: July 13, 2001Date of Patent: September 10, 2002Assignee: Millenium Pharmaceuticals, Inc.Inventor: Gregory J. LaRosa
-
Patent number: 6444802Abstract: The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.Type: GrantFiled: September 30, 1999Date of Patent: September 3, 2002Assignee: Millenium Pharmaceuticals, Inc.Inventors: Rosana Kapeller-Libermann, David White, Immaculada Silos-Santiago
-
Patent number: 6410240Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 4, 2000Date of Patent: June 25, 2002Assignee: Millenium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, David Yowe
-
Patent number: 6403552Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: June 9, 1998Date of Patent: June 11, 2002Assignee: Millenium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Patent number: 6403767Abstract: The present invention provides novel D6 polypeptides and proteins, as well as isolated D6 fusion proteins, antigenic peptides and anti-D6 antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 24, 2000Date of Patent: June 11, 2002Assignees: Millenium Pharmaceuticals, Inc., CRC Technology LimitedInventors: Gerard J. Graham, Robert J. Benjamin Nibbs, Jose-Angel Gonzalo, Jose-Carlos Gutierrez-Ramos
-
Patent number: 6337388Abstract: This invention relates to newly identified auxotrophs, polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production and isolation of such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been putatively identified as being very important to the growth and/or reproduction of Aspergillus fumigatus.Type: GrantFiled: February 4, 2000Date of Patent: January 8, 2002Assignee: Millenium Pharmaceuticals, Inc.Inventor: Vicky Gavrias
-
Patent number: 6306895Abstract: The invention provides new methods for preparation of cyclic oxygen compounds, including 2,5-disubstituted tetahydrofurans, 2,6-disubstituted tetrahydropyrans, 2,7-disubstituted oxepanes and 2,8-oxocanes. The invention also provides new cyclic oxygen compounds and pharmaceutical compositions and therapeutic methods that comprise such compounds.Type: GrantFiled: July 2, 1999Date of Patent: October 23, 2001Assignee: Millenium Pharmaceuticals, Inc.Inventors: Mukund Shankar Chorghade, Mukund Keshao Gurjar, Palakodety Radha Krishna, Sista Venkata Sai Lalitha, Kashinath Sadalapure, Susanta Sekhar Adhikari, Andappan Murugaiah Subbaiah Murugaiah, Batchu Venkateswara Rao, Levadala Murali Krishna, Sunil Vyankatesh Mhaskar, Gangavaram Vasantha Madhava Sharma, Tangallapally Rajendra Prasad, Punna Sreenivas, Vavilala Goverdhan Reddy, Aminul Islam, Alla Venkata Rama Rao, Hymavathi Lanka, Bethi Sridhar Reddy, Chittineni Hari Prasad
-
Patent number: 6207407Abstract: A method for identifying a strain having a conditional lethal mutation which is essential for survival when strain is incubated under restrictive growth, conditions, and methods of identifying gene products and gene functions thereof.Type: GrantFiled: May 6, 1999Date of Patent: March 27, 2001Assignee: Millenium Pharmaceuticals, Inc.Inventors: William Timberlake, Victoria Gavrais
-
Patent number: 6194151Abstract: Novel TRL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TRL proteins, the invention further provides isolated TRL fusion proteins, antigenic peptides and anti-TRL antibodies. The invention also provides TRL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TRL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 17, 1998Date of Patent: February 27, 2001Assignee: Millenium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Patent number: 6174682Abstract: Novel thioredoxin family active site molecules, designated MP-4 polypeptides, proteins, and nucleic acid molecules, are disclosed. In addition to isolated, full-length MP-4 proteins, the invention further provides isolated MP-4 fusion proteins, antigenic peptides and anti-MP-4 antibodies. The invention also provides MP-4 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a MP-4 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 8, 1999Date of Patent: January 16, 2001Assignee: Millenium Pharmaceuticals, Inc.Inventor: Mehran M. Khodadoust
-
Patent number: 6090581Abstract: This invention relates to newly identified auxotrophs, polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production and isolation of such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been putatively identified as being very important to the growth and/or reproduction of Aspergillus fumigatus.Type: GrantFiled: March 18, 1998Date of Patent: July 18, 2000Assignee: Millenium Pharmaceuticals, Inc.Inventor: Vicky Gavrias
-
Patent number: 6031076Abstract: The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: January 5, 1998Date of Patent: February 29, 2000Assignee: Millenium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Carlos J. Gimeno
-
Patent number: 6018025Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: January 25, 2000Assignees: Millenium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 5955306Abstract: The present invention relates to the discovery of novel genes encoding Tub interactor (TI) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: July 21, 1997Date of Patent: September 21, 1999Assignee: Millenium Pharmaceuticals, Inc.Inventors: Carlos J. Gimeno, Patrick R. Errada
-
Patent number: 5914394Abstract: The present invention relates to the mammalian fsh16 gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses fsh16 nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, fsh16 gene products and antibodies directed against such gene products, cloning vectors containing mammalian fsh16 gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of fsh16 and to using such compounds as therapeutic agents in the treatment of fsh16 disorders and neuropsychiatric disorders.Type: GrantFiled: March 27, 1997Date of Patent: June 22, 1999Assignees: Millenium Pharmaceuticals, Inc., The Regents of the University of CaliforniaInventors: Hong Chen, Nelson B. Freimer